Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,029 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL. Orlowski RZ, et al. Among authors: san miguel j. J Clin Oncol. 2007 Sep 1;25(25):3892-901. doi: 10.1200/JCO.2006.10.5460. Epub 2007 Aug 6. J Clin Oncol. 2007. PMID: 17679727 Clinical Trial.
Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A, Granda A, Martínez-Chamorro C, Díaz-Mediavilla J, Martínez R, García-Laraña J, Lahuerta JJ, Sureda A, Bladé J, de la Rubia J, Fernández-Rañada JM, San Miguel J; Spanish Registry of Transplants in Multiple Myelomas; Spanish Group of Hemopoietic Transplant (GETH); PETHEMA. Alegre A, et al. Among authors: san miguel j. Haematologica. 2002 Jun;87(6):609-14. Haematologica. 2002. PMID: 12031917
Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.
Ludwig H, Rai K, Blade J, Dammacco F, Degos L, Itri L, Kyle R, Liso V, Littlewood TJ, Mandelli F, Meloni G, Molica S, Osterborg A, Pangalis GA, San Miguel J, Schmitt B, Voliotis D. Ludwig H, et al. Among authors: san miguel j. Hematol J. 2002;3(3):121-30. doi: 10.1038/sj.thj.6200160. Hematol J. 2002. PMID: 12111647 Review.
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B; Scientific Advisors of the International Myeloma Foundation. Durie BG, et al. Among authors: san miguel j. Hematol J. 2003;4(6):379-98. Hematol J. 2003. PMID: 14671610 Review.
Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR. Kröger N, et al. Among authors: san miguel jf. Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708. doi: 10.1016/j.bbmt.2004.06.002. Biol Blood Marrow Transplant. 2004. PMID: 15389436 Free article. Clinical Trial.
Bortezomib is an efficient agent in plasma cell leukemias.
Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, Schenkein D, Pandiella A, San Miguel JF. Esparís-Ogando A, et al. Among authors: san miguel jf. Int J Cancer. 2005 Apr 20;114(4):665-7. doi: 10.1002/ijc.20793. Int J Cancer. 2005. PMID: 15609327
International staging system for multiple myeloma.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. Greipp PR, et al. Among authors: san miguel j. J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4. J Clin Oncol. 2005. PMID: 15809451
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Richardson PG, et al. Among authors: san miguel jf. N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445. N Engl J Med. 2005. PMID: 15958804 Free article. Clinical Trial.
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Bladé J, Rosiñol L, Sureda A, Ribera JM, Díaz-Mediavilla J, García-Laraña J, Mateos MV, Palomera L, Fernández-Calvo J, Martí JM, Giraldo P, Carbonell F, Callís M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J; Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). Bladé J, et al. Among authors: san miguel j. Blood. 2005 Dec 1;106(12):3755-9. doi: 10.1182/blood-2005-03-1301. Epub 2005 Aug 16. Blood. 2005. PMID: 16105975 Free article. Clinical Trial.
1,029 results